Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Cosmo Feilding Mellen
|
| gptkbp:clinicalTrialPhase |
gptkb:5-MeO-DMT
psilocybin analogues |
| gptkbp:collaboratesWith |
gptkb:Beckley_Foundation
|
| gptkbp:developedBy |
psychedelic-based therapeutics
|
| gptkbp:focusesOn |
treatment-resistant depression
neurological disorders psychedelic medicines |
| gptkbp:foundedBy |
gptkb:Amanda_Feilding
|
| gptkbp:foundedYear |
2019
|
| gptkbp:fundedBy |
gptkb:Series_B
|
| gptkbp:headquartersLocation |
gptkb:Oxford,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Beckley Psytech
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:investor |
gptkb:Adage_Capital_Management
gptkb:B_Capital_Group Satori Neuro |
| gptkbp:mission |
to help patients suffering from neurological and psychiatric disorders by developing psychedelic medicines
|
| gptkbp:raisedFundingAmount |
US$80 million
|
| gptkbp:website |
https://www.beckleypsytech.com/
|
| gptkbp:bfsParent |
gptkb:Cosmo_Feilding-Mellen
|
| gptkbp:bfsLayer |
7
|